BLT 0.00% 2.6¢ benitec biopharma limited

Herald Sun Article

  1. 5,583 Posts.
    lightbulb Created with Sketch. 361
    "TIMING is everything and Benitec Biopharma chief financial officer Greg West was counting his blessings yesterday.
    The innovative gene silencing and replacement company has endured a year of steady preparations for a Nasdaq listing and finalised it last Monday with settlement last Friday.
    Had the offer straddled the past couple of days things could have been very different, with the $US13.8 million of capital raised possibly drying up like a puddle in summer.
    The long game now for Benitec is to do more deals with big US pharmaceutical companies, with its potentially single dose, self-perpetuating cures for a variety of serious disease applications of great interest.
    The main targets are hepatitis B and C, a range of cancers, HIV/AIDS, eye diseases, pain and even the genetic disease Huntington’s but that list could expand.
    A speculative buy with the Nasdaq listing potentially helping the share price over time."
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.